Anteris Technologies Ltd
ASX:AVR

Watchlist Manager
Anteris Technologies Ltd Logo
Anteris Technologies Ltd
ASX:AVR
Watchlist
Price: 9.3 AUD -3.93% Market Closed
Market Cap: 196.6m AUD
Have any thoughts about
Anteris Technologies Ltd?
Write Note

Anteris Technologies Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Anteris Technologies Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Anteris Technologies Ltd
ASX:AVR
Cost of Revenue
-AU$1.6m
CAGR 3-Years
16%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Cost of Revenue
-AU$37.6m
CAGR 3-Years
-18%
CAGR 5-Years
-12%
CAGR 10-Years
-17%
Polynovo Ltd
ASX:PNV
Cost of Revenue
-AU$5.5m
CAGR 3-Years
-52%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
SDI Ltd
ASX:SDI
Cost of Revenue
-AU$42.2m
CAGR 3-Years
-10%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
Ansell Ltd
ASX:ANN
Cost of Revenue
-$994.5m
CAGR 3-Years
7%
CAGR 5-Years
-2%
CAGR 10-Years
0%
Next Science Ltd
ASX:NXS
Cost of Revenue
-$5.9m
CAGR 3-Years
-125%
CAGR 5-Years
-74%
CAGR 10-Years
N/A
No Stocks Found

Anteris Technologies Ltd
Glance View

Market Cap
178.8m AUD
Industry
Health Care

Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.

AVR Intrinsic Value
0.76 AUD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Anteris Technologies Ltd's Cost of Revenue?
Cost of Revenue
-1.6m AUD

Based on the financial report for Dec 31, 2023, Anteris Technologies Ltd's Cost of Revenue amounts to -1.6m AUD.

What is Anteris Technologies Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
34%

Over the last year, the Cost of Revenue growth was 20%. The average annual Cost of Revenue growth rates for Anteris Technologies Ltd have been 16% over the past three years , 34% over the past five years .

Back to Top